HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.58|
|52 Week High||US$6.01|
|52 Week Low||US$20.00|
|1 Month Change||-2.23%|
|3 Month Change||-29.85%|
|1 Year Change||-31.10%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-53.00%|
Recent News & Updates
Checking Back In On HOOKIPA Pharma
Today, we revisit HOOKIPA Pharma for the first time in more than a year and a half. The company aims to develop a novel class of immunotherapeutics targeting infectious diseases and cancers based on their proprietary arenavirus platform that works by reprogramming the body's immune system. A full investment analysis follows in the paragraphs below.
Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers
HOOKIPA Pharma (HOOK) has reported positive Phase 1 data from its ongoing Phase 1/2 study of HB-200 for the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers.Up to the March 31 cut-off date, 38 patients with metastatic HPV16+ tumors had received HB-200 therapy: 14 received HB-201, 8 received alternating HB-201/HB-202, and 16 received other regimens.Immunogenicity data for eight patients with head and neck tumors were available at the time of data cut-off. Arenaviral therapeutic HB-200 therapy induced outstanding tumor-specific CD8+ T
|HOOK||US Biotechs||US Market|
Return vs Industry: HOOK underperformed the US Biotechs industry which returned 26.1% over the past year.
Return vs Market: HOOK underperformed the US Market which returned 31.5% over the past year.
Stable Share Price: HOOK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: HOOK's weekly volatility (6%) has been stable over the past year.
About the Company
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.
HOOKIPA Pharma Fundamentals Summary
|HOOK fundamental statistics|
Is HOOK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HOOK income statement (TTM)|
|Cost of Revenue||US$71.43m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.04|
|Net Profit Margin||-304.07%|
How did HOOK perform over the long term?See historical performance and comparison
Is HOOKIPA Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate HOOK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate HOOK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: HOOK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: HOOK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HOOK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HOOK is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (3.2x).
How is HOOKIPA Pharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HOOK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HOOK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HOOK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HOOK's revenue (53.3% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: HOOK's revenue (53.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HOOK is forecast to be unprofitable in 3 years.
How has HOOKIPA Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HOOK is currently unprofitable.
Growing Profit Margin: HOOK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HOOK is unprofitable, and losses have increased over the past 5 years at a rate of 36.6% per year.
Accelerating Growth: Unable to compare HOOK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HOOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: HOOK has a negative Return on Equity (-48.01%), as it is currently unprofitable.
How is HOOKIPA Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: HOOK's short term assets ($143.5M) exceed its short term liabilities ($33.9M).
Long Term Liabilities: HOOK's short term assets ($143.5M) exceed its long term liabilities ($6.3M).
Debt to Equity History and Analysis
Debt Level: HOOK's debt to equity ratio (3.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if HOOK's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HOOK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HOOK has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 31.9% each year.
What is HOOKIPA Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HOOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HOOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HOOK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HOOK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HOOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joern Aldag (62 yo)
Mr. Joern Aldag has been Chief Executive Officer at Hookipa Biotech GmbH since June 16, 2016. He has been a Director of Hookipa Pharma Inc. since February 2017 and serves as its Chief Executive Officer sin...
CEO Compensation Analysis
Compensation vs Market: Joern's total compensation ($USD1.92M) is above average for companies of similar size in the US market ($USD1.09M).
Compensation vs Earnings: Joern's compensation has been consistent with company performance over the past year.
Experienced Management: HOOK's management team is considered experienced (4.5 years average tenure).
Experienced Board: HOOK's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.5%.
HOOKIPA Pharma Inc.'s employee growth, exchange listings and data sources
- Name: HOOKIPA Pharma Inc.
- Ticker: HOOK
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$196.694m
- Shares outstanding: 29.89m
- Website: https://www.hookipapharma.com
Number of Employees
- HOOKIPA Pharma Inc.
- 350 Fifth Avenue
- 72nd Floor
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 22:45|
|End of Day Share Price||2021/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.